# Basal Cell Carcinoma

Basal cell carcinoma is one of the most biologically logical settings for itraconazole because of the importance of **Hedgehog signalling** in this disease.

### Overview

Itraconazole's Hedgehog-pathway inhibition gives it a particularly strong mechanistic fit in basal cell carcinoma, where blocking the **Smoothened (SMO)** step of the pathway can slow or shrink tumours.

### Key human data

* An open-label phase II trial in **29 patients** with basal cell carcinoma treated **19 patients** with oral itraconazole, using **200 mg twice daily for 1 month** in one cohort and **100 mg twice daily for about 2.3 months** in another.
* Itraconazole reduced tumour-cell proliferation measured by **Ki-67** by about **45%** and reduced Hedgehog-pathway activity measured by **GLI1 mRNA** by about **65%** in tumour biopsies.
* In a subset of patients with multiple unbiopsied tumours, mean tumour area fell by around **24%** after treatment.
* In that same subset, **four of eight** patients had partial responses and **four of eight** had stable disease, while untreated control tumours did not shrink.
* Case reports and small series suggest similar activity in advanced or metastatic basal cell carcinoma and in combination with standard Hedgehog inhibitors, but these data are still very limited.

### Practical interpretation

This is one of the clearest examples of pathway logic and early clinical signal lining up in the same cancer type. Itraconazole hits Hedgehog in the lab and measurably dampens Hedgehog signalling and tumour growth in human basal cell carcinoma.

However, the trial was small and short. Dedicated Hedgehog inhibitors such as **vismodegib** and **sonidegib** have stronger evidence and higher response rates, so itraconazole sits as a repurposed, off-label option rather than standard first-line therapy.

### References

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma\
<https://pubmed.ncbi.nlm.nih.gov/24493717/>

Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth\
<https://www.sciencedirect.com/science/article/pii/S153561081000070X>

Inhibition of the Hedgehog pathway for the treatment of cancer using itraconazole\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6711563/>

Old drug, new target: Itraconazole and basal cell carcinoma\
<https://jpmsonline.com/article/jpms-volume-5-issue-1-pages21-22-ed/>

Itraconazole in the treatment of basal cell carcinoma: case-based experience and combinations with vismodegib\
<https://onlinelibrary.wiley.com/doi/10.1111/ajd.13655>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/basal-cell-carcinoma.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.